Tranquility Partners LLC Sells 467 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tranquility Partners LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,877 shares of the medical research company’s stock after selling 467 shares during the quarter. IQVIA makes up about 0.9% of Tranquility Partners LLC’s holdings, making the stock its 25th biggest position. Tranquility Partners LLC’s holdings in IQVIA were worth $2,270,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Golden State Wealth Management LLC increased its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after buying an additional 130 shares during the last quarter. Strategic Investment Advisors MI bought a new stake in shares of IQVIA during the 1st quarter worth about $377,000. Berry Wealth Group LP increased its holdings in shares of IQVIA by 29.3% during the 1st quarter. Berry Wealth Group LP now owns 1,764 shares of the medical research company’s stock valued at $311,000 after acquiring an additional 400 shares during the last quarter. Sheets Smith Wealth Management raised its stake in shares of IQVIA by 0.3% in the 1st quarter. Sheets Smith Wealth Management now owns 49,150 shares of the medical research company’s stock valued at $8,665,000 after acquiring an additional 155 shares in the last quarter. Finally, Sava Infond d.o.o. raised its position in shares of IQVIA by 4.6% in the first quarter. Sava Infond d.o.o. now owns 10,720 shares of the medical research company’s stock valued at $1,890,000 after purchasing an additional 470 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Hsbc Global Res cut shares of IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Truist Financial decreased their target price on IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research note on Thursday, April 10th. Barclays lowered their target price on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 7th. Mizuho cut their price target on IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $226.32.

IQVIA Price Performance

Shares of IQVIA stock opened at $158.00 on Friday. The firm has a market cap of $27.33 billion, a P/E ratio of 21.53, a price-to-earnings-growth ratio of 1.74 and a beta of 1.28. The firm’s 50-day simple moving average is $148.98 and its 200-day simple moving average is $174.85. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period in the previous year, the business earned $2.54 earnings per share. The company’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.